Peptide Receptor Radionuclide Therapy (PRRT) Market is expanding as Soricimed Biopharma Inc. collaborates with Orano Med to develop a novel PRRT to treat solid tumor cancers
One of the most effective treatment options for patients with metastatic lung cancer is the use of peptide receptor iontophoresis. This procedure involves the injection of a small amount of a peptide, generally an amino acid or carboxylic acid, into the affected tissue where it stimulates a release of energy from the cells. One of the key factors that aid growth of the said market is growing cases of pancreatic neuroendocrine tumor and gastrointestinal tract neuroendocrine tumors. As per the American Cancer Society, in 2021, around 4,200 people in the U.S. are likely to be diagnosed with pancreatic neuroendocrine tumor (NET). Generally, people with pancreatic NETs are aged 60 years and above with the disease being most common in women. PRRT is a unique way to approach neuroendocrine tumors, which could benefit the patient. Hence, these factors can stimulate growth of the peptide receptor radionuclide therapy (PRRT) market. Another key factor fueling growth of the market is cont...